ECSP12011702A - THERAPEUTIC PROTEINS OF UNION TO DLL4 - Google Patents

THERAPEUTIC PROTEINS OF UNION TO DLL4

Info

Publication number
ECSP12011702A
ECSP12011702A ECSP12011702A ECSP12011702A EC SP12011702 A ECSP12011702 A EC SP12011702A EC SP12011702 A ECSP12011702 A EC SP12011702A EC SP12011702 A ECSP12011702 A EC SP12011702A
Authority
EC
Ecuador
Prior art keywords
dll4
angiogenesis
binding proteins
proteins
dll4 binding
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Lorenzo Benatuil
Edwin R Boghaert
Jijie Gu
Maria Harris
Jonathan Hickson
Chung Ming Hsieh
Yuliya Kutskova
Yingchun Li
Zhihomg Liu
Lappe Susan Morgan
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52281168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011702(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP12011702A publication Critical patent/ECSP12011702A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen proteínas de unión a DLL4 mejoradas, se incluyen anticuerpos, anticuerpos con CDR injertadas, anticuerpos humanos, y fragmentos de unión a DLL4 de los mismos, proteínas que se unen a DLL4 con alta afinidad, y proteínas de unión a DLL4 que neutralizan la actividad de DLL4. Las proteínas de unión a DLL4 son útiles para tratar o prevenir cáncer y tumores, especialmente para el tratamiento o la prevención de la angiogénesis tumoral, y/u otras enfermedades dependientes de angiogénesis tales como la neovascularización ocular, o enfermedades independientes de la angiogénesis caracterizadas por expresión o actividad aberrante de DLL4 tal como trastornos autoinmune que incluyen la esclerosis múltiple.Improved DLL4 binding proteins are described, including antibodies, grafted CDR antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind to DLL4 with high affinity, and DLL4 binding proteins that neutralize the DLL4 activity. DLL4 binding proteins are useful for treating or preventing cancer and tumors, especially for the treatment or prevention of tumor angiogenesis, and / or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant expression or activity of DLL4 such as autoimmune disorders that include multiple sclerosis.

ECSP12011702 2009-08-29 2012-02-29 THERAPEUTIC PROTEINS OF UNION TO DLL4 ECSP12011702A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23815209P 2009-08-29 2009-08-29

Publications (1)

Publication Number Publication Date
ECSP12011702A true ECSP12011702A (en) 2012-04-30

Family

ID=52281168

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011702 ECSP12011702A (en) 2009-08-29 2012-02-29 THERAPEUTIC PROTEINS OF UNION TO DLL4

Country Status (2)

Country Link
EC (1) ECSP12011702A (en)
UA (1) UA105397C2 (en)

Also Published As

Publication number Publication date
UA105397C2 (en) 2014-05-12

Similar Documents

Publication Publication Date Title
CO6612215A2 (en) Therapeutic proteins binding to dll4
CY1121148T1 (en) VEGF / DLL4 CONNECTING FACTORS AND THEIR USES
CO6612264A2 (en) Therapeutic proteins of the binding to dll 4
EA201790404A1 (en) MACROPINOCYTOZING HUMAN ANTI-CD46 ANTIBODIES AND TARGET TREATMENT OF CANCER
IN2015KN00350A (en)
CY1123926T1 (en) ANTIBODIES AGAINST TRANSGLUTAMINASE 2
CO2022002573A2 (en) Antibodies against ilt2 and their use
EA201201464A1 (en) NEW COMBINED THERAPY FOR THE TREATMENT OF CANCER AND FIBROUS DISEASES
EP2175879A4 (en) Treatment of prion protein related diseases
MX2021010766A (en) Tsg-6 antibodies and uses therefor.
NZ789100A (en) Bispecific anti-ccl2 antibodies
BR112016023011A2 (en) gastric cancer treatment
WO2012158933A3 (en) Macrocycllc therapeutic agents and methods of treatment
ECSP12011702A (en) THERAPEUTIC PROTEINS OF UNION TO DLL4
MX2022008061A (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8.
EA202192254A1 (en) FCMR-BINDING MOLECULES AND THEIR APPLICATION
MA40363A (en) Rspo1 binding agents and uses thereof
EA202092151A1 (en) ANTIBODIES
TH157534A (en) Protein binding DLL4 that heals disease